<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Midodrine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Midodrine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Midodrine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10861" href="/d/html/10861.html" rel="external">see "Midodrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709087"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because midodrine can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of midodrine in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured 1 minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine, principally improved ability to carry out activities of daily living, have not been verified.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867561"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Amatine;</li>
<li>APO-Midodrine;</li>
<li>JAMP-Midodrine;</li>
<li>MAR-Midodrine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F196568"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha<sub>1</sub> Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F196542"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="debc0dc2-f06b-40ac-98e8-1728d2a1c3a7">Ascites, cirrhotic, diuretic resistant or with hypotension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascites, cirrhotic, diuretic resistant or with hypotension (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 7.5 mg 3 times daily; adjust dose in increments of 2.5 mg per dose (eg, increase from 5 mg 3 times daily to 7.5 mg 3 times daily) every 24 hours to achieve target mean arterial pressure; maximum dose: 17.5 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463403','lexi-content-ref-Runyon.1','lexi-content-ref-21749847','lexi-content-ref-19238094','lexi-content-ref-30312183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463403','lexi-content-ref-Runyon.1','lexi-content-ref-21749847','lexi-content-ref-19238094','lexi-content-ref-30312183'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20767005-7d0c-4775-983f-285973f8d164">Hemodialysis-induced hypotension, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis-induced hypotension, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used in conjunction with other therapy adjustments for preventing recurrent intradialytic hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg given 15 to 30 minutes prior to hemodialysis. If response is insufficient, may increase up to 10 mg given 15 to 30 minutes prior to the next hemodialysis session; if hypotension occurs near the end of hemodialysis, may give an additional 2.5 to 5 mg dose mid-dialysis provided it is administered ≥3 hours after pre-dialysis dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9398120','lexi-content-ref-9725781','lexi-content-ref-8861803','lexi-content-ref-Henrich.1','lexi-content-ref-KDOQI.2005','lexi-content-ref-15280522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9398120','lexi-content-ref-9725781','lexi-content-ref-8861803','lexi-content-ref-Henrich.1','lexi-content-ref-KDOQI.2005','lexi-content-ref-15280522'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="741f2f95-4bbd-4f0b-a86f-9280d55d9dc0">Hepatorenal syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatorenal syndrome type 1 or acute kidney injury, treatment (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative to norepinephrine or terlipressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg 3 times daily in combination with albumin and octreotide; adjust dose (eg, by 2.5 to 5 mg per dose) as needed after each 8-hour dosing interval, with an immediate goal of increasing mean arterial pressure by ~10 to 15 mm Hg; maximum dose: 15 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-10347109','lexi-content-ref-17235705','lexi-content-ref-19455106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-10347109','lexi-content-ref-17235705','lexi-content-ref-19455106'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ee801e8-feb6-4e9c-9d52-c77be3e4476e">Hypotension in the ICU, vasopressor sparing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension in the ICU, vasopressor sparing (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> According to some experts, may be useful to facilitate discontinuation of low-dose IV vasopressors; prospective data are limited. Reevaluate therapy regularly, including at each transition of care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506565','lexi-content-ref-29613861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506565','lexi-content-ref-29613861'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg every 8 hours; titrate based on response and tolerability; usual dose: 10 to 20 mg every 8 hours; maximum reported dose: 40 mg every 8 hours. When hemodynamically stable, taper and discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30506565','lexi-content-ref-31030630','lexi-content-ref-23845791','lexi-content-ref-26945564','lexi-content-ref-29613861','lexi-content-ref-26953217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30506565','lexi-content-ref-31030630','lexi-content-ref-23845791','lexi-content-ref-26945564','lexi-content-ref-29613861','lexi-content-ref-26953217'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f10c8c65-4b71-4be1-9bc2-8765d48275a5">Hypotension, symptomatic orthostatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension, symptomatic orthostatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Individual doses &gt;10 mg and total daily doses &gt;30 mg can cause severe supine hypertension and bradycardia. Adjust dose or discontinue if supine BP increases excessively.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg 2 or 3 times daily during daytime hours (eg, every 3 to 4 hours) when patient is upright; titrate as needed based on response and tolerability up to a usual maximum dose of 10 mg 3 times daily. Avoid administering &lt;4 hours before bedtime to minimize risk of supine hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562304','lexi-content-ref-Palma.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562304','lexi-content-ref-Palma.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b2d2bcf-2892-4c38-946f-df5b5abfc5de">Postural orthostatic tachycardia syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postural orthostatic tachycardia syndrome (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg 3 times daily (eg, morning, midday, and late afternoon); may increase gradually (eg, every 3 to 4 days) in increments of 2.5 mg/dose (eg, may increase from 2.5 mg 3 times daily to 5 mg 3 times daily) to a maximum of 10 mg 3 times daily. Avoid administering &lt;4 hours before bedtime to minimize risk of supine hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23978222','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23978222','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8201240f-8353-4bc0-86df-20c3e061c4d3">Syncope, vasovagal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syncope, vasovagal (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in patients with recurrent syncope despite nonpharmacologic measures. Regularly reassess dose (eg, every 3 to 6 months) and need for continued use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Benditt.1','lexi-content-ref-29562304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Benditt.1','lexi-content-ref-29562304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg 3 times daily during daytime hours (eg, every 4 to 6 hours administered in morning, at noon, and late afternoon) when patient is upright; adjust dose and frequency as needed based on response and tolerability; usual dosage range: 2.5 mg twice daily to 10 mg 3 times daily; maximum reported dose: 15 mg 3 times daily. Avoid administering &lt;4 hours before bedtime to minimize risk of supine hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562304','lexi-content-ref-11513446','lexi-content-ref-34339231','lexi-content-ref-9505918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562304','lexi-content-ref-11513446','lexi-content-ref-34339231','lexi-content-ref-9505918'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990240"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Limited pharmacokinetic data available in kidney impairment. Desglymidodrine (active metabolite) is primarily renally eliminated and half-life is prolonged from 3 to 4 hours in patients with normal kidney function to 9 to 10 hours in patients with end-stage kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8712208','lexi-content-ref-18791956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8712208','lexi-content-ref-18791956'])">Ref</a></span>). Although generally reported to be well-tolerated, midodrine-induced vascular ischemia has been reported in a dialysis patient with underlying peripheral vascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18791956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18791956'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73m<sup>2</sup>: Initiate with a low dose (eg, 2.5 mg 1 to 3 times daily); increase to indication-specific dose as needed based on tolerability and response; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Dialyzable (extent undetermined) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8712208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8712208'])">Ref</a></span>): Initiate with a low dose (eg, 2.5 mg 1 to 2 times daily); increase to indication-specific dose as needed based on tolerability and response; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). For use in the treatment of hemodialysis-induced hypotension, refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Likely to be dialyzable (low protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Initiate with a low dose (eg, 2.5 mg 1 to 2 times daily); increase to indication-specific dose as needed based on tolerability and response; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Likely to be dialyzed: Initiate with doses on the lower end of the indication-specific recommended range and increase as needed based on tolerability and response; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT:</b> Likely to be dialyzed: Initiate with doses on the lower end of the indication-specific recommended range and increase as needed based on tolerability and response; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987371"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doe drugH1Div" id="F196543"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55758848"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradycardia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Midodrine may cause <b>bradycardia</b> primarily due to vagal reflex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498780','lexi-content-ref-32885276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498780','lexi-content-ref-32885276'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the vasoconstrictive pharmacologic action; thought to be due to activation of the baroreceptor reflex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32885276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32885276'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27417951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27417951'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications with negative chronotropic effects (eg, beta-blockers, digoxin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sick sinus syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498780'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Supine hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Midodrine may cause <b>supine</b>
<b>hypertension. </b>Supine increases of 16 to 18 mm Hg have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32204870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32204870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the vasoconstrictive pharmacologic action. Increases blood pressure and vascular tone by stimulating arterial and venous alpha receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27372462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27372462'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33687577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33687577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Supine position (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28050656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28050656'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline blood pressure elevations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33687577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33687577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of vasoconstrictors (eg, phenylephrine, ephedrine, dihydroergotamine, phenylpropanolamine, pseudoephedrine)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F196511"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Piloerection (13%), pruritus (12%; mainly of the scalp)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (13%; including urinary frequency, urinary retention, urinary urgency)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Supine hypertension (7%; increased systolic blood pressure [~200 mmHg]: 13%)<span class="lexi-table-link-container"> (<a aria-label="Supine Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-supine-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-supine-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Supine Hypertension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Supine Hypertension" frame="border" id="lexi-content-supine-hypertension" rules="all">
<caption style="text-align:center;">
<b>Midodrine: Adverse Reaction: Supine Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Midodrine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Midodrine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">82</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">88</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Increased systolic blood pressure (~200 mmHg)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (5%), pain (5%; including abdominal pain)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis, flatulence, gastrointestinal distress, heartburn, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness, hyperesthesia (skin), insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, back pain, lower limb cramp</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual field defect</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking, anxiety, confusion, headache, nervousness, sensation of pressure (intracranial)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Cordeiro 2019), vascular disease (Rubenstein 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Sadeghpour 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (Horger 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell (Horger 2016), myoclonus (Ye 2020)</p></div>
<div class="block coi drugH1Div" id="F196523"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe organic heart disease; acute renal disease; urinary retention; pheochromocytoma; thyrotoxicosis; supine hypertension; poorly controlled hypertension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to midodrine or any component of the formulation; obliterative or spastic vessel disease; renal insufficiency; hypertrophy of prostate gland with formation of residual urine; hyperthyroidism; narrow angle glaucoma.</p></div>
<div class="block war drugH1Div" id="F196508"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; midodrine is a prodrug metabolized to an active metabolite (desglymidodrine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Desglymidodrine, the active metabolite, is primarily renally excreted; assess renal function prior to initial dose; use with caution in patients with renal impairment (has not been studied) and initiate with a reduced dose; contraindicated in patients with acute renal failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual problems: Use with caution in patients with visual problems, especially if receiving fludrocortisone.</p></div>
<div class="block foc drugH1Div" id="F196518"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F196504"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F196524"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Midodrine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.03 - $1.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.04 - $4.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.84 - $9.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867562"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amatine: 10 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F196520"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Doses may be given in approximately 3- to 4-hour intervals (eg, shortly before or upon rising in the morning, at midday, in the late afternoon not later than 6 PM). Avoid dosing after the evening meal or within 4 hours of bedtime to prevent supine hypertension.</p></div>
<div class="block use drugH1Div" id="F196519"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypotension, symptomatic orthostatic: </b>Treatment of symptomatic orthostatic hypotension.</p></div>
<div class="block off-label drugH1Div" id="F25730552"><span class="drugH1">Use: Off-Label: Adult</span><p>Ascites, cirrhotic, diuretic resistant or with hypotension; Hemodialysis-induced hypotension, prevention; Hepatorenal syndrome type 1 or acute kidney injury, treatment; Hypotension in the ICU, vasopressor sparing; Postural orthostatic tachycardia syndrome; Syncope, vasovagal</p></div>
<div class="block mst drugH1Div" id="F196575"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Midodrine may be confused with midostaurin, Midrin, minoxidil</p>
<p style="text-indent:-2em;margin-left:4em;">ProAmatine may be confused with protamine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299710"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F196513"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider delaying skin testing until alpha1-agonists are no longer required, or use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: Midodrine may enhance the bradycardic effect of Bradycardia-Causing Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Midodrine may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F196525"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies. Information related to the use of midodrine in pregnancy is limited (Glatter 2005).</p></div>
<div class="block brc drugH1Div" id="F20616331"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if midodrine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering midodrine to nursing women.</p></div>
<div class="block mop drugH1Div" id="F196516"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP while supine, sitting, and standing upon awakening; signs or symptoms of bradycardia; renal and hepatic function.</p></div>
<div class="block pha drugH1Div" id="F196507"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Midodrine forms an active metabolite, desglymidodrine, which is an alpha<sub>1</sub>-agonist. This agent increases arteriolar and venous tone resulting in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with orthostatic hypotension.</p></div>
<div class="block phk drugH1Div" id="F196522"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: ~1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 2 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Poorly crosses blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Minimal </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic and many other tissues; midodrine is a prodrug which undergoes rapid deglycination to desglymidodrine (active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Desglymidodrine: 93% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Desglymidodrine: ~3 to 4 hours; Midodrine: 25 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Desglymidodrine: 1 to 2 hours; Midodrine: 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (Midodrine: Insignificant; Desglymidodrine: 80% by active renal secretion)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F196526"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo midodrine | Gutron</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Vasodrine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An de lin | Gutron | Mi wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Midodrina | Syncopgor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Midodrine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Hypotron</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Midodrine arrow | Midodrine biogaran | Midodrine mylan | Midodrine teva | Midodrine zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bramox | Gutron | Midodrine | Midotense</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bramox | Midodrine tillomed | Midon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actiful | Cipmido | Gutron | Hypodrin | Inramed | Midgeo | Midodrive | Midohep | Midora | Midorise | Midotab | Xidorin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Abalnate | Metligine | Metodrin | Natildine | Shuprase | Shuprase nichiiko | Shuprase ohara</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Midron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Midodrine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Midodrine | Proamatine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hypotron</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Midodrine HCL | Orvaten | Proamatine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Limbron | Midodrine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hypotron | Midodrin | Midodrin abacus medicine | Midodrin ebb | Midodrin medartuum</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Midorine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Gutron | Midorine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gutron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10347109">
<a name="10347109"></a>Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. <i>Hepatology</i>. 1999;29(6):1690-1697.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/10347109/pubmed" id="10347109" target="_blank">10347109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Midodrine.1">
<a name="Midodrine.1"></a>APO-Midodrine [product monograph]. Toronto, Ontario, Canada: Apotex Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benditt.1">
<a name="Benditt.1"></a>Benditt D. Reflex syncope in adults and adolescents: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8712208">
<a name="8712208"></a>Blowey DL, Balfe JW, Gupta I, Gajaria MM, Koren G. Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. <i>Am J Kidney Dis</i>. 1996;28(1):132-136. doi:10.1016/s0272-6386(96)90142-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/8712208/pubmed" id="8712208" target="_blank">8712208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562304">
<a name="29562304"></a>Brignole M, Moya A, de Lange FJ, et al; ESC Scientific Document Group. 2018 ESC guidelines for the diagnosis and management of syncope. <i>Eur Heart J.</i> 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/29562304/pubmed" id="29562304" target="_blank">29562304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30506565">
<a name="30506565"></a>Buckley MS, Barletta JF, Smithburger PL, Radosevich JJ, Kane-Gill SL. Catecholamine vasopressor support sparing strategies in vasodilatory shock. <i>Pharmacotherapy</i>. 2019;39(3):382-398. doi:10.1002/phar.2199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/30506565/pubmed" id="30506565" target="_blank">30506565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31498780">
<a name="31498780"></a>Cordeiro N, Gupta SS, Lindsay D, Seneviratne C, Kulbak G, Kupfer Y. Midodrine: associated bradycardia. <i>Am J Ther</i>. 2019;26(5):e655-e656. doi:10.1097/MJT.0000000000000856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/31498780/pubmed" id="31498780" target="_blank">31498780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9725781">
<a name="9725781"></a>Cruz DN, Mahnensmith RL, Brickel HM, et al. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. <i>Clin Nephrol. </i>1998;50(2):101-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/9725781/pubmed" id="9725781" target="_blank">9725781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9398120">
<a name="9398120"></a>Cruz DN, Mahnensmith RL, Perazella MA. Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? <i>Am J Kidney Dis</i>. 1997;30(6):772-779. doi:10.1016/s0272-6386(97)90081-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/9398120/pubmed" id="9398120" target="_blank">9398120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17235705">
<a name="17235705"></a>Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. <i>Dig Dis Sci</i>. 2007;52(3):742-748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/17235705/pubmed" id="17235705" target="_blank">17235705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8861803">
<a name="8861803"></a>Flynn JJ 3rd, Mitchell MC, Caruso FS, McElligott MA. Midodrine treatment for patients with hemodialysis hypotension. <i>Clin Nephrol</i>. 1996;45(4):261-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/8861803/pubmed" id="8861803" target="_blank">8861803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19455106">
<a name="19455106"></a>Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program [published correction appears in <i>Am J Gastroenterol</i>. 2009;104(7):1894]. <i>Am J Gastroenterol</i>. 2009;104(7):1802-1829.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/19455106/pubmed" id="19455106" target="_blank">19455106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28050656">
<a name="28050656"></a>Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. <i>J Neurol</i>. 2017;264(8):1567-1582. doi:10.1007/s00415-016-8375-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/28050656/pubmed" id="28050656" target="_blank">28050656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15955196">
<a name="15955196"></a>Glatter KA, Tuteja D, Chiamvimonvat N, et al, "Pregnancy in Postural Orthostatic Tachycardia Syndrome," <i>Pacing Clin Electrophysiol</i>, 2005, 28(6):591-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/15955196/pubmed" id="15955196" target="_blank">15955196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10750641">
<a name="10750641"></a>Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. <i>Clin Auton Res</i>. 2000;10(1):29-33. doi:10.1007/bf02291387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/10750641/pubmed" id="10750641" target="_blank">10750641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31030630">
<a name="31030630"></a>Hammond DA, Smith MN, Peksa GD, Trivedi AP, Balk RA, Menich BE. Midodrine as an adjuvant to intravenous vasopressor agents in adults with resolving shock: systematic review and meta-analysis [published online April 28, 2019]. <i>J Intensive Care Med</i>. doi:10.1177/0885066619843279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/31030630/pubmed" id="31030630" target="_blank">31030630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Henrich.1">
<a name="Henrich.1"></a>Henrich WL, Flythe JE. Intradialytic hypotension in an otherwise stable patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26811341">
<a name="26811341"></a>Horger S, Kandrac S, Longyhore DS. Taste and smell disturbance resulting from midodrine. <i>J Pharm Pract</i>. 2016;29(6):571-573. doi:10.1177/0897190015627403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/26811341/pubmed" id="26811341" target="_blank">26811341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33687577">
<a name="33687577"></a>Isaacson SH, Dashtipour K, Mehdirad AA, Peltier AC. Management strategies for comorbid supine hypertension in patients with neurogenic orthostatic hypotension. <i>Curr Neurol Neurosci Rep</i>. 2021;21(4):18.doi:10.1007/s11910-021-01104-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/33687577/pubmed" id="33687577" target="_blank">33687577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9244228">
<a name="9244228"></a>Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. <i>Circulation</i>. 1997;96(2):575-580. doi:10.1161/01.cir.96.2.575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/9244228/pubmed" id="9244228" target="_blank">9244228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JampMidodrine.1">
<a name="JampMidodrine.1"></a>Jamp Midodrine tablets, USP (midodrine) [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaufmann.1">
<a name="Kaufmann.1"></a>Kaufmann H, Freeman R. Postural tachycardia syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23845791">
<a name="23845791"></a>Levine AR, Meyer MJ, Bittner EA, et al. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. <i>J Crit Care</i>. 2013;28(5):756-762. doi:10.1016/j.jcrc.2013.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/23845791/pubmed" id="23845791" target="_blank">23845791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9091692">
<a name="9091692"></a>Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group [published correction appears in <i>JAMA.</i> 1997;278(5):388]. <i>JAMA</i>. 1997;277(13):1046-1051.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/9091692/pubmed" id="9091692" target="_blank">9091692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Midodrine.2">
<a name="Midodrine.2"></a>Midodrine Hydrochloride [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.2005">
<a name="KDOQI.2005"></a>National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. <i>Am J Kidney Dis. </i>2005;45(suppl 3):S1-S154. http://www.kidney.org/sites/default/files/docs/cvd__in_dialysis_composite_gl.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32204870">
<a name="32204870"></a>Olshansky B, Muldowney J. Cardiovascular safety considerations in the treatment of neurogenic orthostatic hypotension. <i>Am J Cardiol</i>. 2020;125(10):1582-1593. doi:10.1016/j.amjcard.2020.01.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/32204870/pubmed" id="32204870" target="_blank">32204870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Palma.1">
<a name="Palma.1"></a>Palma JA, Kaufmann H. Treatment of orthostatic and postprandial hypotension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11513446">
<a name="11513446"></a>Perez-Lugones A, Schweikert R, Pavia S, et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. <i>J Cardiovasc Electrophysiol.</i> 2001;12(8):935-938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/11513446/pubmed" id="11513446" target="_blank">11513446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945564">
<a name="26945564"></a>Poveromo LB, Michalets EL, Sutherland SE. Midodrine for the weaning of vasopressor infusions. <i>J Clin Pharm Ther</i>. 2016;41(3):260-265. doi:10.1111/jcpt.12375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/26945564/pubmed" id="26945564" target="_blank">26945564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15280522">
<a name="15280522"></a>Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. <i>Nephrol Dial Transplant.</i> 2004;19(10):2553-2558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/15280522/pubmed" id="15280522" target="_blank">15280522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32145864">
<a name="32145864"></a>Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. <i>Can J Cardiol.</i> 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/32145864/pubmed" id="32145864" target="_blank">32145864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29613861">
<a name="29613861"></a>Rizvi MS, Trivedi V, Nasim F, et al. Trends in use of midodrine in the ICU: a single-center retrospective case series. <i>Crit Care Med</i>. 2018;46(7):e628-e633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/29613861/pubmed" id="29613861" target="_blank">29613861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23978222">
<a name="23978222"></a>Ross AJ, Ocon AJ, Medow MS, Stewart JM. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome.<i> Clin Sci (Lond)</i>. 2014;126(4):289-296. doi:10.1042/CS20130222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/23978222/pubmed" id="23978222" target="_blank">23978222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18791956">
<a name="18791956"></a>Rubinstein S, Haimov M, Ross MJ. Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review. <i>Ren Fail</i>. 2008;30(8):808-812. doi:10.1080/08860220802249025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/18791956/pubmed" id="18791956" target="_blank">18791956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA. Ascites in adults with cirrhosis: diuretic-resistant ascites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2">
<a name="Runyon.2"></a>Runyon BA. Hepatorenal syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2012">
<a name="Runyon.2012"></a>Runyon BA; American Association for the Study of Liver Diseases Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. <i>Hepatology</i>. https://www.aasld.org/sites/default/files/2019-06/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf. Published February 2013. Accessed April 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897147">
<a name="24897147"></a>Sadeghpour M, Bunick CG, Robinson DM, Galan A, Tigelaar RE, Imaeda S. Midodrine-induced acute generalized exanthematous pustulosis. <i>Cutis</i>. 2014;93(5):E17-E20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/24897147/pubmed" id="24897147" target="_blank">24897147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885276">
<a name="32885276"></a>Santer P, Anstey MH, Patrocínio MD, et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. <i>Intensive Care Med</i>. 2020;46(10):1884-1893. doi:10.1007/s00134-020-06216-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/32885276/pubmed" id="32885276" target="_blank">32885276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34339231">
<a name="34339231"></a>Sheldon R, Faris P, Tang A, et al; POST 4 investigators. Midodrine for the prevention of vasovagal syncope: a randomized clinical trial. <i>Ann Intern Med</i>. 2021;174(10):1349-1356. doi:10.7326/M20-5415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/34339231/pubmed" id="34339231" target="_blank">34339231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980576">
<a name="25980576"></a>Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i>. 2015;12(6):e41-e63. doi:10.1016/j.hrthm.2015.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/25980576/pubmed" id="25980576" target="_blank">25980576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28286247">
<a name="28286247"></a>Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2017;14(8):e155-e217. doi:10.1016/j.hrthm.2017.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/28286247/pubmed" id="28286247" target="_blank">28286247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21749847">
<a name="21749847"></a>Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. <i>J Hepatol</i>. 2012;56(2):348-354. doi:10.1016/j.jhep.2011.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/21749847/pubmed" id="21749847" target="_blank">21749847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19238094">
<a name="19238094"></a>Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. <i>J Clin Gastroenterol</i>. 2009;43(7):680-685. doi:10.1097/MCG.0b013e318188947c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/19238094/pubmed" id="19238094" target="_blank">19238094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27372462">
<a name="27372462"></a>Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. <i>Clin Auton Res</i>. 2016;26(4):269-277. doi:10.1007/s10286-016-0363-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/27372462/pubmed" id="27372462" target="_blank">27372462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9505918">
<a name="9505918"></a>Ward CR, Gray JC, Gilroy JJ, et al. Midodrine: a role in the management of neurocardiogenic syncope. <i>Heart.</i> 1998;79(1):45-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/9505918/pubmed" id="9505918" target="_blank">9505918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26953217">
<a name="26953217"></a>Whitson MR, Mo E, Nabi T, et al. Feasibility, utility, and safety of midodrine during recovery phase from septic shock. <i>Chest</i>. 2016;149(6):1380-1383. doi:10.1016/j.chest.2016.02.657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/26953217/pubmed" id="26953217" target="_blank">26953217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27417951">
<a name="27417951"></a>Wong LY, Wong A, Robertson T, Burns K, Roberts M, Isbister GK. Severe hypertension and bradycardia secondary to midodrine overdose. <i>J Med Toxicol</i>. 2017;13(1):88-90. doi:10.1007/s13181-016-0574-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/27417951/pubmed" id="27417951" target="_blank">27417951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33019383">
<a name="33019383"></a>Ye X, Ling B, Wu J, et al. Case report: severe myoclonus associated with oral midodrine treatment for hypotension. <i>Medicine (Baltimore)</i>. 2020;99(40):e21533. doi:10.1097/MD.0000000000021533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/33019383/pubmed" id="33019383" target="_blank">33019383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30312183">
<a name="30312183"></a>Yosry A, Soliman ZA, Eletreby R, Hamza I, Ismail A, Elkady MA. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. <i>Eur J Gastroenterol Hepatol.</i> 2019;31(3):345-351. doi:10.1097/MEG.0000000000001277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midodrine-drug-information/abstract-text/30312183/pubmed" id="30312183" target="_blank">30312183</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9651 Version 335.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
